Key Takeaways
- • Sofinnova Partners closed Sofinnova Capital XI at €650 million ($750 million), significantly exceeding its initial fundraising target, with strong backing from sovereign wealth funds, pharma companies, insurance firms, foundations, and family offices.
- • The €650 million fund will deploy capital across early-stage biotech and medtech companies in Europe and the US, with a focus on both initial financings and follow-on investment rounds addressing unmet clinical needs.
- • This fundraise brings Sofinnova's total capital raised in the preceding 12 months to €1.5 billion, with the firm managing assets exceeding €4 billion across biopharma, medtech, industrial biotech, and digital medicine categories.
- • Managing partner Antoine Papiernik characterized the fund closure as a "pivotal moment," enabling Sofinnova to "double down on early-stage opportunities" while reinforcing its science-driven, collaborative investment approach.
- • The successful close demonstrates robust institutional appetite for European life sciences venture capital despite volatile market conditions, following comparable large fund closures in the sector such as Medicxi's €500 million sixth fund.
Summary
Sofinnova Partners, a Paris-based early-stage life sciences venture capital firm, has closed Sofinnova Capital XI at €650 million (approximately $750 million), substantially surpassing its original fundraising target. The fund achieved strong institutional support from a diversified investor base including sovereign wealth funds, pharmaceutical corporations, insurance companies, foundations, and family offices, underscoring sustained confidence in European life sciences investments despite a volatile market environment.
The capital will be deployed to support pioneering biopharmaceutical and medical technology companies across Europe and the North American markets, with particular emphasis on enterprises addressing urgent unmet clinical needs. According to Sofinnova, the fund is actively deploying capital with investments already executed, and will pursue both initial financings and follow-on rounds with portfolio companies.
The €650 million close represents a significant inflection point for Sofinnova's fundraising trajectory. The firm raised €1.5 billion in total capital during the preceding 12 months and is managing funds exceeding €4 billion in assets under management. Earlier in the year, Sofinnova reported raising €1.2 billion with sufficient dry powder to support 50 to 60 life science companies, having backed over 500 companies since its establishment in the early 1970s.
Managing partner Antoine Papiernik characterized the fund's closure as pivotal, stating it "gives us the firepower to double down on early-stage opportunities and reinforces our uniquely collaborative, science-driven investment approach." The firm's portfolio spans biopharma, medtech, industrial biotech, and digital medicine, providing broad exposure across the healthcare innovation ecosystem.
The successful close aligns with positive momentum in European life sciences venture capital, evidenced by comparable recent fund closures such as Anglo-Swiss firm Medicxi's €500 million sixth fund, indicating sustained institutional capital availability for seasoned managers with established track records in the sector.
The capital will be deployed to support pioneering biopharmaceutical and medical technology companies across Europe and the North American markets, with particular emphasis on enterprises addressing urgent unmet clinical needs. According to Sofinnova, the fund is actively deploying capital with investments already executed, and will pursue both initial financings and follow-on rounds with portfolio companies.
The €650 million close represents a significant inflection point for Sofinnova's fundraising trajectory. The firm raised €1.5 billion in total capital during the preceding 12 months and is managing funds exceeding €4 billion in assets under management. Earlier in the year, Sofinnova reported raising €1.2 billion with sufficient dry powder to support 50 to 60 life science companies, having backed over 500 companies since its establishment in the early 1970s.
Managing partner Antoine Papiernik characterized the fund's closure as pivotal, stating it "gives us the firepower to double down on early-stage opportunities and reinforces our uniquely collaborative, science-driven investment approach." The firm's portfolio spans biopharma, medtech, industrial biotech, and digital medicine, providing broad exposure across the healthcare innovation ecosystem.
The successful close aligns with positive momentum in European life sciences venture capital, evidenced by comparable recent fund closures such as Anglo-Swiss firm Medicxi's €500 million sixth fund, indicating sustained institutional capital availability for seasoned managers with established track records in the sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.